Dong, Y., Li, Y., Zhang, Y., Sun, D., Du, Q., Zhang, T., . . . Wang, T. (2020). Clinical Efficacy and Cost-Effectiveness of β-Lactam/β-Lactamase Inhibitor Combinations and Carbapenems in Liver Cirrhosis Patients with Gram-Negative Bacteria Bloodstream Infection. Infect Drug Resist.
Citación estilo ChicagoDong, Yuzhu, et al. "Clinical Efficacy and Cost-Effectiveness of β-Lactam/β-Lactamase Inhibitor Combinations and Carbapenems in Liver Cirrhosis Patients With Gram-Negative Bacteria Bloodstream Infection." Infect Drug Resist 2020.
Cita MLADong, Yuzhu, et al. "Clinical Efficacy and Cost-Effectiveness of β-Lactam/β-Lactamase Inhibitor Combinations and Carbapenems in Liver Cirrhosis Patients With Gram-Negative Bacteria Bloodstream Infection." Infect Drug Resist 2020.